Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D M Eccles

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
Clinical Dysmorphology|April 1, 1994
Prenatal ultrasound findings in a fetus with otopalatodigital syndrome type IID M Eccles, I E Moore, S Cook, et al.
Journal of Medical Genetics|September 1, 2010
A novel HER2-positive breast cancer phenotype arising from germline TP53 mutationsJ R F Wilson, A C Bateman, H Hanson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2015
BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significanceD M Eccles, G Mitchell, A N A Monteiro, et al.
Journal of Medical Genetics|June 3, 2004
A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPROD G R Evans, D M Eccles, N Rahman, et al.
Journal of Medical Genetics|April 1, 1994
Adenomatous polyposis coli and a cytogenetic deletion of chromosome 5 resulting from a maternal intrachromosomal insertionJ C Barber, K H Ellis, L V Bowles, et al.
Clinical Dysmorphology|April 1, 1995
Craniofacial abnormalities, agenesis of the corpus callosum, polysyndactyly and abnormal skin and gut development--the Curry Jones syndromeI K Temple, D M Eccles, R M Winter, et al.
British Journal of Cancer|August 1, 1995
Chromosome 11 allele imbalance and clinicopathological correlates in ovarian tumoursH Gabra, L Taylor, B B Cohen, et al.
Archives of Disease in Childhood|March 6, 1998
An unusually severe phenotype for familial adenomatous polyposisD M Eccles, P W Lunt, Y Wallis, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1991
Mitozantrone and prednimustine in the treatment of advanced breast cancer--a toxic regimen with low activityM E O'Brien, D M Eccles, S G Allen, et al.
Cancer Research|May 1, 1993
p53 mutation is a common genetic event in ovarian carcinomaB J Milner, L A Allan, D M Eccles, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Clinical Dysmorphology|April 1, 1994
Prenatal ultrasound findings in a fetus with otopalatodigital syndrome type IID M Eccles, I E Moore, S Cook, et al.
Journal of Medical Genetics|September 1, 2010
A novel HER2-positive breast cancer phenotype arising from germline TP53 mutationsJ R F Wilson, A C Bateman, H Hanson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2015
BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significanceD M Eccles, G Mitchell, A N A Monteiro, et al.
Journal of Medical Genetics|June 3, 2004
A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPROD G R Evans, D M Eccles, N Rahman, et al.
Journal of Medical Genetics|April 1, 1994
Adenomatous polyposis coli and a cytogenetic deletion of chromosome 5 resulting from a maternal intrachromosomal insertionJ C Barber, K H Ellis, L V Bowles, et al.
Clinical Dysmorphology|April 1, 1995
Craniofacial abnormalities, agenesis of the corpus callosum, polysyndactyly and abnormal skin and gut development--the Curry Jones syndromeI K Temple, D M Eccles, R M Winter, et al.
British Journal of Cancer|August 1, 1995
Chromosome 11 allele imbalance and clinicopathological correlates in ovarian tumoursH Gabra, L Taylor, B B Cohen, et al.
Archives of Disease in Childhood|March 6, 1998
An unusually severe phenotype for familial adenomatous polyposisD M Eccles, P W Lunt, Y Wallis, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1991
Mitozantrone and prednimustine in the treatment of advanced breast cancer--a toxic regimen with low activityM E O'Brien, D M Eccles, S G Allen, et al.
Cancer Research|May 1, 1993
p53 mutation is a common genetic event in ovarian carcinomaB J Milner, L A Allan, D M Eccles, et al.
Pageof 6